{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060209","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.086864+00:00","generated_at":"2026-06-08T14:32:15.565901+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biodesix Q3 2023: Lung diagnostic revenue up 34% YoY; net loss narrows 20%","bullets":["Total revenue $13.5M (+21% YoY); lung diagnostics $12.3M (+34% YoY); Biopharma Services $1.2M (+79% YoY).","Lung diagnostic test volume >10,400 (+60% YoY); gross margin improved to 76% from 67%.","Net loss $10.9M (-20% YoY); Adjusted EBITDA loss $5.4M (-40% YoY).","FY 2023 revenue guidance lowered to $50-52M due to Medicare Advantage backlog removal; core business unchanged.","Cash $19.8M at Sep 30; additional $10M draw from Perceptive term loan and final $12.2M private placement expected in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060209","json":"https://secwatch.observer/filing/0000950170-23-060209.json","markdown":"https://secwatch.observer/filing/0000950170-23-060209.md","text":"https://secwatch.observer/filing/0000950170-23-060209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023060209/0000950170-23-060209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023060209/bdsx-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:32:15.565901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b631f7049d9da83b8989f3bbbbe0a7f1c2eae524","claim":"BIODESIX INC reported third quarter ended September 30, 2023 results: revenue $13.5 million, net income $10.9 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue of $13.5 million, an increase of 21%, including COVID testing revenue in third quarter 2022, driven primarily by strong year-over-year growth in lung diagnostics, and a 37% year-over-year increase excluding COVID testing revenues from the prior year comparison;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023060209/0000950170-23-060209-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$13.5 million"},{"label":"Net income","value":"$10.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}